We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+4.9%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$265M
AUM Growth
+$37.5M
(+17%)
Cap. Flow
+$34M
Cap. Flow
% of AUM
12.86%
Top 10 Holdings %
Top 10 Hldgs %
9.25%
Holding
421
New
24
Increased
206
Reduced
145
Closed
45
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DT Midstream
DTM
|
+$1.85M |
| 2 |
Delek US
DK
|
+$898K |
| 3 |
ScottsMiracle-Gro
SMG
|
+$843K |
| 4 |
Valero Energy
VLO
|
+$783K |
| 5 |
FMC
FMC
|
+$709K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
COR
Coresite Realty Corporation
COR
|
+$1.67M |
| 2 |
XLRN
Acceleron Pharma
XLRN
|
+$601K |
| 3 |
VTA
INVESCO DYNAMIC CREDIT OPPORTUNITIES FUND
VTA
|
+$551K |
| 4 |
KDMN
Kadmon Holdings, Inc.
KDMN
|
+$448K |
| 5 |
Travere Therapeutics
TVTX
|
+$434K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Real Estate | 22.39% |
| 2 | Healthcare | 18.38% |
| 3 | Energy | 15.88% |
| 4 | Materials | 14.07% |
| 5 | Utilities | 13.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CERE
251
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $179K | 0.07% |
5,525
-10,142
| -65% | -$358K |
|
252
AbCellera Biologics
ABCL
$1.62B
| $178K | 0.07% |
12,482
+3,818
| +44% | +$57.9K |
|
253
Arcturus Therapeutics
ARCT
$163M
| $178K | 0.07% |
4,803
-1,110
| -19% | -$45.2K |
|
254
Fulcrum Therapeutics
FULC
$248M
| $178K | 0.07% |
+10,059
| New | +$199K |
|
255
Praxis Precision Medicines
PRAX
$8.25B
| $178K | 0.07% |
602
-82
| -12% | -$24.1K |
|
256
Cogent Biosciences
COGT
$6.95B
| $177K | 0.07% |
20,610
-2,725
| -12% | -$23.7K |
|
|
CMRX
257
DELISTED
Chimerix, Inc.
CMRX
| $177K | 0.07% |
27,514
+2,361
| +9% | +$14.2K |
|
|
ADAP
258
DELISTED
Adaptimmune Therapeutics
ADAP
| $176K | 0.07% |
46,931
-419
| -0.9% | -$1.91K |
|
259
Curis
CRIS
$9.41M
| $176K | 0.07% |
92
+26
| +39% | +$61.8K |
|
260
ImmunityBio
IBRX
$7.3B
| $176K | 0.07% |
28,969
+14,725
| +103% | +$111K |
|
|
RPTX
261
DELISTED
Repare Therapeutics
RPTX
| $176K | 0.07% |
8,355
+1,873
| +29% | +$44.1K |
|
|
MYOV
262
DELISTED
Myovant Sciences Ltd.
MYOV
| $176K | 0.07% |
11,289
+1,534
| +16% | +$29.3K |
|
|
AKRO
263
DELISTED
Akero Therapeutics
AKRO
| $175K | 0.07% |
8,266
+1,120
| +16% | +$24.8K |
|
264
Iovance Biotherapeutics
IOVA
$2.1B
| $175K | 0.07% |
9,182
+281
| +3% | +$6.19K |
|
|
MORF
265
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $175K | 0.07% |
3,693
+420
| +13% | +$22.5K |
|
266
Nurix Therapeutics
NRIX
$2.51B
| $174K | 0.07% |
6,010
-1,183
| -16% | -$35.9K |
|
|
MRTX
267
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $174K | 0.07% |
1,183
-66
| -5% | -$10.2K |
|
268
Compugen
CGEN
$214M
| $173K | 0.07% |
40,161
+15,182
| +61% | +$82.1K |
|
|
DVAX
269
DELISTED
Dynavax Technologies
DVAX
| $173K | 0.07% |
12,277
-11,295
| -48% | -$186K |
|
270
Precigen
PGEN
$1.97B
| $173K | 0.07% |
46,531
+16,382
| +54% | +$70.5K |
|
271
Rhythm Pharmaceuticals
RYTM
$7.41B
| $173K | 0.07% |
17,290
+7,061
| +69% | +$79.3K |
|
|
KYNB
272
Kyntra Bio
KYNB
$28.2M
| $172K | 0.07% |
489
+160
| +49% | +$49.8K |
|
273
Prelude Therapeutics
PRLD
$370M
| $172K | 0.07% |
13,815
+7,523
| +120% | +$122K |
|
|
VBIV
274
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $172K | 0.07% |
+2,444
| New | +$206K |
|
|
KNTE
275
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $172K | 0.07% |
+9,725
| New | +$205K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
RC
Virtus ETF Advisers's Q4 2021 Portfolio in Review
As of Q4 2021, Virtus ETF Advisers held 421 positions worth $265M, up 17% from $227M the previous quarter. Its ten largest holdings account for 9.2% of the portfolio.
Virtus ETF Advisers deployed $34M of net new capital in Q4 2021, opening 24 new positions and adding to 206 existing holdings. Its largest new stake was Invivyd: 22,625 shares worth $164K.
By sector, the portfolio is most concentrated in Real Estate at 22% of assets, up from 20% a quarter earlier, followed by Healthcare and Energy.
On the sell side, the largest reduction was Travere Therapeutics, an estimated $434K trimmed.
- Virtus ETF Advisers's largest Q4 2021 buy was Invivyd: 22,625 shares worth $164K.
- Virtus ETF Advisers added most to DT Midstream in Q4 2021, an estimated $1.85M increase.
- Virtus ETF Advisers's biggest Q4 2021 reduction was Travere Therapeutics, cutting an estimated $434K.
- Virtus ETF Advisers fully exited Coresite Realty Corporation in Q4 2021, selling an estimated $1.67M.
- Virtus ETF Advisers's ten largest holdings make up 9.2% of its $265M portfolio in Q4 2021.
- Virtus ETF Advisers opened 24 new positions and closed 45 in Q4 2021.
- Virtus ETF Advisers's portfolio value rose 17% quarter-over-quarter to $265M.
Based on Virtus ETF Advisers's 13F filing for Q4 2021, filed 14 Feb 2022.